Subgroup analysis was further carried out to explore the potential sources of heterogeneity.Īmong the 1,579 eligible patients, 1,164 (73.7%) underwent lobectomy and 415 (26.3%) underwent sublobar resection (106 segmentectomy and 309 wedge resection). ![]() Perioperative outcomes and overall survival were analyzed by using propensity score matching to adjust for selection bias. Clinical data on demographic and tumor characteristics, surgical details were collected. Clinical stage I NSCLC patients who underwent lobar or sublobar resection (segmentectomy and wedge resection) at the Department of Thoracic Surgery of 10 tertiary hospitals between January 2014 and September 2017 were retrospectively reviewed from the national collaborative prospective lung cancer database (LinkDoc Technology Co, Ltd., Beijing, China). This is a multicenter retrospective cohort study. lobectomy for management of elderly patients (≥65 years) with clinical stage I NSCLC. The present study aimed to comparatively study the perioperative outcomes and overall survival of sublobar resection vs. However, controversy remains as to whether it is adequate for elderly patients. Sublobar resection has emerged as an alternative to lobectomy for management of early-stage non-small cell lung cancer (NSCLC). 12 Medical Affairs, LinkDoc Technology Co, Ltd., Beijing 100080, China.11 Department of Thoracic Surgery, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China.10 Department of Thoracic Surgery, Tianjin Chest Hospital, Tianjin 300051, China.9 Department of Thoracic Surgery, Henan Cancer Hospital, Zhengzhou 450008, China.8 Jiangsu Key Laboratory of Molecular and Translational Cancer Research, Cancer Institute of Jiangsu Province, Nanjing 210009, China.7 Department of Thoracic Surgery, Nanjing Medical University Affiliated Cancer Hospital, Cancer Institute of Jiangsu Province, Nanjing 210009, China.6 Department of Thoracic Surgery, Tangdu Hospital, Fourth Military Medical University, Xi'an 710038, China.5 Department of Thoracic Surgery, Chinese People's Liberation Army General Hospital, Beijing 1000853, China.4 Department of Thoracic Surgery, West China Hospital, Sichuan University, Chengdu 610041, China.3 Department of Thoracic Surgery, First Hospital Affiliated to Medical College of Zhejiang University, Hangzhou 310000, China.2 Department of Thoracic Surgery, Shanghai Chest Hospital, Shanghai 200030, China.1 Department of Thoracic Surgery, China-Japan Friendship Hospital, Beijing 100029, China.listing by a Chinese firm on record, after Alibaba Group Holding Ltd.’s $25 billion blockbuster debut in 2014. this year, according to data compiled by Bloomberg. Its investors include Alibaba Health Information Technology Ltd., MBK Partners, New Enterprise Associates and Temasek Holdings Pte according to a preliminary filing.Ĭhinese companies have raised about $13 billion through first-time share sales in the U.S. LinkDoc, founded in 2014, provides cancer focused health-care services built on big data and artificial intelligence, its website shows. A representative for LinkDoc declined to comment. Reuters reported LinkDoc’s IPO halt earlier Thursday. LinkDoc’s IPO delay also comes as regulators in Beijing are planning rule changes that would allow them to block a Chinese company from listing overseas even if the unit selling shares is incorporated outside China, closing a loophole long-used by the country’s technology giants, Bloomberg News reported this week. plunged after the government ordered the removal of the ride-hailing giant’s app from local app stores within days of its $4.4 billion U.S. were arranging the deal.Ĭhinese technology stocks suffered a rout after China signaled a new era of tighter oversight over cybersecurity. ![]() ![]() ![]() LinkDoc was slated to price the offering on Thursday, which could have raised as much as $211 million. Market volatility has played a part in the postponement and the Beijing-based medical data company could revisit its listing plans when conditions improve, said one of the people, who asked not to be identified as the information is private. initial public offering, people familiar with the matter said, the first known company to pull out of a debut after China’s government cracked down on overseas listings.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |